ReviewTargeted oncology2012
Risk management of biosimilars in oncology: each medicine is a work in progress.
Arnold G Vulto et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ReviewTargeted oncology2012
Arnold G Vulto et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.